Search Results - "Farnell, Michael B."

Differences in Clinical Profile and Relapse Rate of Type 1 Versus Type 2 Autoimmune Pancreatitis by Sah, Raghuwansh P, Chari, Suresh T, Pannala, Rahul, Sugumar, Aravind, Clain, Jonathan E, Levy, Michael J, Pearson, Randall K, Smyrk, Thomas C, Petersen, Bret T, Topazian, Mark D, Takahashi, Naoki, Farnell, Michael B, Vege, Santhi S

“…Background & Aims Autoimmune pancreatitis (AIP) has been divided into subtypes 1 (lymphoplasmacytic sclerosing pancreatitis) and 2 (idiopathic duct centric…”
Get full text

Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database by Shubert, Christopher R., MD, Bergquist, John R., MD, Groeschl, Ryan T., MD, Habermann, Elizabeth B., PhD, Wilson, Patrick M., MPH, Truty, Mark J., MD, Smoot, Rory L., MD, Kendrick, Michael L., MD, Nagorney, David M., MD, Farnell, Michael B., MD

“…Background Outcomes of neoadjuvant systemic therapy versus an upfront operation for clinical, stage III pancreatic adenocarcinoma remain poorly defined. Our…”
Get full text

Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early-Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study by Bergquist, John R., MS, MA, MD, Puig, Carlos A., MD, Shubert, Christopher R., MD, Groeschl, Ryan T., MD, Habermann, Elizabeth B., MPH, PhD, Kendrick, Michael L., MD, FACS, Nagorney, David M., MD, FACS, Smoot, Rory L., MD, Farnell, Michael B., MD, FACS, Truty, Mark J., MS, MD

“…Background Patient triage in anatomically resectable, early-stage pancreatic ductal adenocarcinoma (PDAC) with elevated carbohydrate antigen 19-9 (CA 19-9)…”
Get full text

Immunoglobulin G4–Associated Cholangitis: Clinical Profile and Response to Therapy by Ghazale, Amaar, Chari, Suresh T, Zhang, Lizhi, Smyrk, Thomas C, Takahashi, Naoki, Levy, Michael J, Topazian, Mark D, Clain, Jonathan E, Pearson, Randall K, Petersen, Bret T, Vege, Santhi Swaroop, Lindor, Keith, Farnell, Michael B

“…Background & Aims: Immunoglobulin (Ig)G4-associated cholangitis (IAC) is the biliary manifestation of a steroid-responsive multisystem fibroinflammatory…”
Get full text

Clinical Risk Score to Predict Pancreatic Fistula after Pancreatoduodenectomy: Independent External Validation for Open and Laparoscopic Approaches by Shubert, Christopher R., MD, Wagie, Amy E., MHA, Farnell, Michael B., MD, FACS, Nagorney, David M., MD, FACS, Que, Florencia G., MD, FACS, Reid Lombardo, KMarie, MD, Truty, Mark J., MD, Smoot, Rory L., MD, Kendrick, Michael L., MD, FACS

“…Background A clinical risk score for pancreatic fistula (CRS-PF) was recently reported to predict postoperative pancreatic fistula (POPF) after…”
Get full text

Surgical Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement by Evans, Douglas B., Farnell, Michael B., Lillemoe, Keith D., Vollmer, Charles, Strasberg, Steven M., Schulick, Richard D.

Get full text

Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors by Halfdanarson, Thorvardur R, Rubin, Joseph, Farnell, Michael B, Grant, Clive S, Petersen, Gloria M

“…Pancreatic endocrine tumors (PETs) are uncommon tumors with an annual incidence <1 per 100 000 person-years in the general population. The PETs that produce…”
Get full text

EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer by Levy, Michael J., MD, Alberts, Steven R., MD, Bamlet, William R., MS, Burch, Patrick A., MD, Farnell, Michael B., MD, Gleeson, Ferga C., MD, Haddock, Michael G., MD, Kendrick, Michael L., MD, Oberg, Ann L., PhD, Petersen, Gloria M., PhD, Takahashi, Naoki, MD, Chari, Suresh T., MD

“…Background and Aims Among the greatest hurdles to pancreatic cancer (PC) therapy is the limited tissue penetration of systemic chemotherapy because of tumor…”
Get full text

EUS-guided pancreatic duct intervention: outcomes of a single tertiary-care referral center experience by Fujii, Larissa L., MD, Topazian, Mark D., MD, Abu Dayyeh, Barham K., MD, Baron, Todd H., MD, Chari, Suresh T., MD, Farnell, Michael B., MD, Gleeson, Ferga C., MD, Gostout, Christopher J., MD, Kendrick, Michael L., MD, Pearson, Randall K., MD, Petersen, Bret T., MD, Truty, Mark J., MD, Vege, Santhi S., MD, Levy, Michael J., MD

“…Background EUS can provide access to the main pancreatic duct (MPD) for therapeutic intervention. The long-term clinical success of EUS-guided MPD…”
Get full text

Adjuvant Chemoradiation for Pancreatic Adenocarcinoma: The Johns Hopkins Hospital—Mayo Clinic Collaborative Study by Hsu, Charles C., Herman, Joseph M., Corsini, Michele M., Winter, Jordan M., Callister, Matthew D., Haddock, Michael G., Cameron, John L., Pawlik, Timothy M., Schulick, Richard D., Wolfgang, Christopher L., Laheru, Daniel A., Farnell, Michael B., Swartz, Michael J., Gunderson, Leonard L., Miller, Robert C.

“…Background Survival for pancreatic ductal adenocarcinoma is low, the role of adjuvant therapy remains controversial, and recent data suggest adjuvant…”
Get full text

Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis by Bergquist, John R., Ivanics, Tommy, Storlie, Curtis B., Groeschl, Ryan T., Tee, May C., Habermann, Elizabeth B., Smoot, Rory L., Kendrick, Michael L., Farnell, Michael B., Roberts, Lewis R., Gores, Gregory J., Nagorney, David M., Truty, Mark J.

“…Background Optimal management of patients with intrahepatic cholangiocarcinoma (ICCA) and elevated CA19‐9 remains undefined. We hypothesized CA19‐9 elevation…”
Get full text

Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005) by CORSINI, Michele M, MILLER, Robert C, LOTT, Matthew J, GUNDERSON, Leonard L, HADDOCK, Michael G, DONOHUE, John H, FARNELL, Michael B, NAGORNEY, David M, JATOI, Aminah, MCWILLIAMS, Robert R, KIM, George P, BHATIA, Sumita

“…To determine prognostic factors and impact of adjuvant chemotherapy (CT) and radiotherapy (RT) on overall survival (OS) after resection of pancreatic…”
Get full text

Pancreatic anastomotic leakage after pancreaticoduodenectomy in 1,507 patients: a report from the Pancreatic Anastomotic Leak Study Group by Reid-Lombardo, Kaye M, Farnell, Michael B, Crippa, Stefano, Barnett, Matthew, Maupin, George, Bassi, Claudio, Traverso, L William

“…Several definitions for pancreatic leakage after pancreaticodoudenectomy exist, and the reported range of 2-50% underscores this variation. The goal was to…”
Get full text

Prosthetic Graft Reconstruction after Portal Vein Resection in Pancreaticoduodenectomy: A Multicenter Analysis by Chu, Carrie K., MD, Farnell, Michael B., MD, FACS, Nguyen, Justin H., MD, FACS, Stauffer, John A., MD, Kooby, David A., MD, FACS, Sclabas, Guido M., MD, Sarmiento, Juan M., MD, FACS

“…Background Use of prosthetic grafts for reconstruction after portal vein (PV) resection during pancreaticoduodenectomy is controversial. We examined outcomes…”
Get full text

Low Mortality and High Morbidity in Severe Acute Pancreatitis Without Organ Failure: A Case for Revising the Atlanta Classification to Include "Moderately Severe Acute Pancreatitis" by SWAROOP VEGE, Santhi, GARDNER, Timothy B, CHARI, Suresh T, MUNUKUTI, Padma, PEARSON, Randall K, CLAIN, Jonathan E, PETERSEN, Bret T, BARON, Todd H, FARNELL, Michael B, SARR, Michael G

“…Organ failure (OF) is a main cause of death in severe acute pancreatitis (SAP). Our primary aim was to evaluate the morbidity and mortality of patients…”
Get full text

Do Consensus Indications for Resection in Branch Duct Intraductal Papillary Mucinous Neoplasm Predict Malignancy? A Study of 147 Patients by PELAEZ-LUNA, Mario, CHARI, Suresh T, KENDRICK, Michael, FARNELL, Michael B, SMYRK, Thomas C, TAKAHASHI, Naoki, CLAIN, Jonathan E, LEVY, Michael J, PEARSON, Randall K, PETERSEN, Bret T, TOPAZIAN, Mark D, VEGE, Santhi S

“…Recent consensus guidelines suggest that presence of > or =1 of the following is an indication for resection (IR) of branch duct intraductal papillary mucinous…”
Get full text

Disconnected pancreatic duct syndrome in severe acute pancreatitis: clinical and imaging characteristics and outcomes in a cohort of 31 cases by Pelaez-Luna, Mario, MD, Vege, Santhi Swaroop, MD, Petersen, Bret T., MD, Chari, Suresh T., MD, Clain, Jonathan E., MD, Levy, Michael J., MD, Pearson, Randal K., MD, Topazian, Mark D., MD, Farnell, Michael B., MD, Kendrick, Michael L., MD, Baron, Todd H., MD

“…Background Information regarding the natural history, clinical characteristics, and outcomes of disconnected pancreatic duct syndrome (DPDS) is limited…”
Get full text

Diagnosis and Treatment of Mirizzi Syndrome: 23-Year Mayo Clinic Experience by Erben, Young, MD, Benavente-Chenhalls, Luis A., MD, Donohue, John M., MD, FACS, Que, Florencia G., MD, FACS, Kendrick, Michael L., MD, FACS, Reid-Lombardo, Kaye M., MD, FACS, Farnell, Michael B., MD, FACS, Nagorney, David M., MD, FACS

“…Background Mirizzi syndrome (MS) is characterized by extrinsic compression of the common hepatic duct by stones impacted in the cystic duct or gallbladder…”
Get full text

Surgical Management of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas by Farnell, Michael B.

“…Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is characterized by papillary growths within the pancreatic ductal system that are at risk for…”
Get full text

Survival after Resection for Invasive Intraductal Papillary Mucinous Neoplasm and for Pancreatic Adenocarcinoma: A Multi-Institutional Comparison According to American Joint Committee on Cancer Stage by Waters, Joshua A., MD, Schnelldorfer, Thomas, MD, FACS, Aguilar-Saavedra, Juan R., MD, Chen, Jey-Hsin, MD, PhD, Yiannoutsos, Constantin T., PhD, Lillemoe, Keith D., MD, FACS, Farnell, Michael B., MD, FACS, Sarr, Michael G., MD, FACS, Schmidt, C. Max, MD, PhD, MBA, FACS

“…Background Survival after resection for invasive intraductal papillary mucinous neoplasm (inv-IPMN) is superior to pancreatic ductal adenocarcinoma (PDAC)…”
Get full text